BRAF and neoplasm: Anti-PD-1 therapy combined with MEK inhibition produced lasting tumor regression in CT26-innoculated BALB/c mice [223] and the triple therapy with trametinib (MEK inhibitor), dabrafenib (BRAF inhibitor) and anti-PD-1 showed a strong anti-tumor effect [224].